Exposure and measurementsAny idea how long it took for the reductions to take place?
The baseline measurement period (non-exposure period) was defined as within 12 months before the start of ARB or CCB monotherapy. The exposure period (outcome measurement period) was defined as between 2 and 12 months after the start of ARB or CCB monotherapy. The mean exposure of ARB users and CCB users was 243.2 days and 242.1 days, respectively. Laboratory data, including serum levels of triglyceride (TG), total choles- terol (TC), non-fasting blood glucose, hemoglobin A1c (HbA1c), creatinine, sodium, potassium, alanine amino- transferase (ALT), aspartate aminotransferase (AST), and gamma-glutamyltransferase (GGT), hemoglobin, hema- tocrit, and white blood cell (WBC), red blood cell (RBC) and platelet (PLT) counts, were collected for each individ- ual at the date nearest the start of ARB or CCB mono- therapy in the baseline period, and at the date nearest 12 months after the start of ARB or CCB monotherapy in the exposure period.